Duke LifePoint Healthcare Names Dr. Harry Phillips Chief Medical Officer

BRENTWOOD, Tenn. & RALEIGH, N.C.--(BUSINESS WIRE)--Duke LifePoint Healthcare, a joint venture of Duke University Health System and LifePoint Health (NASDAQ: LPNT), today announced that Harry R. Phillips, III, MD, FACC, FSCAI, has been appointed its chief medical officer (CMO). Phillips is also professor of medicine at Duke University School of Medicine, associate director of the Duke Heart Center, and chief medical officer, Duke Network Services, for Duke University Health System.

As Duke LifePoint CMO, Phillips will provide clinical leadership for Duke LifePoint entities designed to improve quality of care, provide clinical insight into strategic planning and foster collaboration with hospital CMOs and other physician leaders to support medical staff alignment. He will also play an integral role in the implementation of Duke LifePoint’s population health strategy and physician engagement activities. Phillips will be part of the Eastern Group leadership team, which guides the operations of Duke LifePoint’s 14-hospital network.

“Dr. Phillips has been an important part of Duke LifePoint’s operations since its founding in 2011,” said Victor Giovanetti, president of LifePoint Health’s Eastern Group, which includes all Duke LifePoint facilities. “His voice as a physician and clinical leader has been a powerful influence within our system. This new role is a natural evolution for him as we continue to expand Duke LifePoint’s footprint and refine the ways we are making communities healthier together. We are delighted to have him on board as Duke LifePoint’s first chief medical officer.”

As Chief Medical Officer of Duke Network Services, Phillips provides physician leadership in developing affiliated clinical programs in multiple specialties at community hospitals throughout the country. His efforts focus on program development, quality oversight, and physician engagement at the affiliated hospitals and practices. Phillips also has been a physician leader for Duke LifePoint since 2011. He has served on various Duke LifePoint hospital boards and physician advisory councils and was part of the team responsible for developing and supporting the Duke Quality Network.

“I am honored to expand my role at Duke LifePoint Healthcare,” said Phillips. “I was fortunate to be among the leaders who supported the founding of Duke LifePoint, and over the last six years, the Duke and LifePoint teams have collaborated to create a strong network of hospitals and healthcare providers that is transforming the delivery of care. We have exciting opportunities for growth ahead of us, and I’m looking forward to exploring how we can contribute in even more meaningful ways to improving the health and wellbeing of the communities we serve.”

Phillips received his MD from Duke University School of Medicine and completed internal medicine and cardiology training at the Harvard-affiliated program at Massachusetts General Hospital. An investigator in the field of interventional cardiology, he has authored or coauthored more than 100 peer-reviewed articles. He is the recipient of the Triangle Business Journal 2017 Healthcare Heroes Lifetime Achievement Award.

About Duke LifePoint Healthcare

Duke LifePoint Healthcare, a joint venture of Duke University Health System, Inc., and LifePoint Health (NASDAQ: LPNT), was established to build a dynamic network of hospitals and healthcare providers. The joint venture, which brings together LifePoint's experience in community-based hospital management and Duke's world-renowned leadership in patient safety and clinical quality systems, is strengthening and improving healthcare delivery by providing community hospitals the clinical, quality and operational resources they need to grow and prosper. www.dukelifepointhealthcare.com

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.